F16
Based on 1 Customer Validation
F16 is a mitochondrial permeability transition pore (PTP) modulator with an EC50 of 30 μM in mice. F16 promotes PTP opening, accumulates in cancer cell mitochondria, and induces mitochondrial depolarization, swelling, cristae disruption, outer membrane rupture, ATP depletion, reactive oxygen species (ROS) production, cytochrome c release and mitochondrial uncoupling. F16 induces cell cycle arrest at the G1 (occasionally G2) phase, reduces the phosphotyrosine content of Neu, as well as the levels of phosphorylated PKB/Akt and phosphorylated MAP kinase, downregulates the protein expression levels of Neu and PKB, triggers apoptosis in cells with moderate Bcl-2 expression, and induces necrosis in cells with overexpressed Bcl-2. F16 can be used in research related to breast cancer and gastric cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.67%
- CAS 番号: 36098-33-6
- 分子式: C16H15IN2
- 分子量:362.21
-
保管条件:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
|
PTP 30 μM (EC50) |
PKB |
Akt |
MAP |
Neu |
Bcl-2 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SGC-7901 | IC50 |
3.45 μM
|
Inhibits SGC-7901 cells growth.
Inhibits SGC-7901 cells growth.
|
29069523 |
| MCF7 | IC50 |
18.99 μM
|
Inhibits mcf-7 cells growth.
Inhibits mcf-7 cells growth.
|
29069523 |
| GES1 | IC50 |
41.79 μM
|
Inhibits GES-1 cells growth.
Inhibits GES-1 cells growth.
|
29069523 |
| HEK293 | IC50 |
38.49 μM
|
Inhibits HEK-293 cells growth.
Inhibits HEK-293 cells growth.
|
29069523 |
F16 (100 nM-15 μM; 36-40 h) selectively inhibits proliferation of EpH4-A6 neu-overexpressing mouse mammary epithelial cells, with partial inhibition observed at concentrations as low as 100 nM[1].
F16 (3 μM; 3-7 days) inhibits proliferation of neu-, v-Ha-ras-, and β-catenin-initiated mouse mammary tumor cell lines and most human breast cancer cell lines[1].
F16 (3 μM; 36 h-3 days) induces cell cycle arrest (primarily G1 arrest) in EpH4-A6 neu-overexpressing mouse mammary epithelial cells and sensitive mouse and human breast tumor cell lines[1].
F16 (24 h) induces S phase cell cycle arrest in SGC-7901 cells after 24 h of incubation[3].
F16 (3 μM; 15-72 h) induces apoptosis in EpH4-A6 neu-overexpressing mouse mammary epithelial cells, characterized by oligonucleosomal DNA fragmentation, Annexin V positivity, and cytochrome c release, but does not induce apoptosis in EpH4-EV control cells[1].
F16 (0.3-3 μM; 48 h) induces oligonucleosomal DNA fragmentation (apoptosis) in apoptosis-sensitive EpH4-A6 and SMF cells, but not in apoptosis-resistant EpH4, Bcl-2-overexpressing EpH4-A6.C13, EpH4-A6.C18, SMF-Bcl-2, or NF324-1C cells[2].
F16 (3 μM; 18-36 h) induces cytochrome c release (an apoptotic marker) in apoptosis-sensitive EpH4-A6 cells within 18 h, but not in apoptosis-resistant Bcl-2-overexpressing EpH4-A6.C13 and EpH4-A6.C18 cells, where delayed cytochrome c localization changes are associated with mitochondrial breakdown rather than apoptosis[2].
F16 (3 μM; 24 h) induces caspase-3 activation (an apoptotic marker) in apoptosis-sensitive EpH4-A6 and SMF cells, but not in apoptosis-resistant Bcl-2-overexpressing EpH4-A6.C13, EpH4-A6.C18, SMF-Bcl-2, or NF324-1C cells[2].
F16 (Various concentrations; 24 h) induces apoptosis in SGC-7901 cells in a concentration-dependent manner after 24 h of incubation[3].
F16 (3 μM; 2-24 h) accumulates selectively in mitochondria of sensitive mouse and human mammary tumor/transformed epithelial cell lines, but not in resistant normal or tumor cell lines[1].
F16 (3 μM; 1 h) accumulation in mitochondria is driven and retained by the mitochondrial transmembrane potential (ΔΨm), and lack of accumulation in resistant cell lines is not mediated by MDR-1 or MRP-1 pumps[1].
F16 (1 μM; 1 h) does not alter accumulation in EpH4-A6 cells due to Bcl-2 overexpression, with F16-sensitive cell lines showing higher mitochondrial accumulation than F16-resistant cell lines[2].
F16 (3-50 μM; 15-72 h) compromises mitochondrial structure and function in sensitive cells, causing swelling, ATP depletion, superoxide production, permeability transition pore opening, and altered respiration, leading to cytotoxicity[1].
F16 (3 μM; 24-48 h) downregulates Neu-dependent signaling in EpH4-A6 neu-overexpressing mouse mammary epithelial cells, reducing phosphorylation of Neu, PKB, and MAPK, and decreasing Neu and PKB protein levels[1].
F16 (3 μM; 24-96 h) induces a time-dependent reduction in cell number in apoptosis-sensitive EpH4-A6 and SMF cells, as well as apoptosis-resistant Bcl-2-overexpressing EpH4-A6.C13, EpH4-A6.C18, SMF-Bcl-2, and NF324-1C cells, with a 3 μM concentration causing up to 32-fold reduction in cell number over 96 h in EpH4-A6 cells[2].
F16 (3 μM; 24-48 h) induces apoptosis in EpH4-A6 cells and necrosis in Bcl-2-overexpressing EpH4-A6.C13 and EpH4-A6.C18 cells; caspase inhibition reduces F16-induced death in EpH4-A6 cells, while buffering ATP levels and neutralizing superoxide reduces necrotic death in Bcl-2-overexpressing cells[2].
F16 (3 μM; 48 h) induces apoptotic morphological changes in EpH4-A6 cells and necrotic morphological changes in Bcl-2-overexpressing EpH4-A6.C13 cells after 48 h of incubation[2].
F16 (3 μM; 15-48 h) induces a time-dependent decrease in cellular ATP levels in both apoptosis-sensitive EpH4-A6 and SMF cells, and apoptosis-resistant Bcl-2-overexpressing EpH4-A6.C13, EpH4-A6.C18, SMF-Bcl-2, and NF324-1C cells, with a 50-60% reduction in ATP levels observed after treatment in SMF-derived and NF324-1C cells[2].
F16 (48 h) has its cytotoxicity on SGC-7901 cells almost completely reversed by ATP pre-treatment 0.5 h before F16, indicating that decreased intracellular ATP availability is a major factor in F16-mediated cytotoxicity[3].
F16 (3 μM; 15-72 h) induces a time-dependent increase in superoxide anion levels in apoptosis-sensitive EpH4-A6 cells and apoptosis-resistant Bcl-2-overexpressing EpH4-A6.C13 and EpH4-A6.C18 cells, but not in F16-resistant EpH4-EV cells[2].
F16 (48 h) potently inhibits proliferation of SGC-7901 and MCF-7 cancer cells with over 10-fold selectivity for SGC-7901 cells over non-tumor GES-1 cells[3].
F16 (48 h) increases intracellular ROS levels in SGC-7901 cells after 48 h of incubation, with partial reversal by pre-treatment with reductants[3].
F16 (3 µM; 24 h) selectively accumulates in the mitochondria of SGC-7901 cells after 24 h of incubation at 3 µM[3].
F16 (48 h) reduces intracellular ATP levels in SGC-7901 cells after 48 h of incubation, with no additional effect at higher concentrations[3].
F16 (10 µM; higher concentrations) induces dose-dependent structural damage to isolated rat liver mitochondria, including swelling at 10 µM and membrane rupture at higher concentrations[3].
F16 enhances H+ and K+ permeabilization of the inner membrane of isolated rat liver mitochondria in a concentration-dependent manner[3].
F16 immediately increases the membrane fluidity of isolated rat liver mitochondria, as measured by reduced fluorescence anisotropy of HP-labeled mitochondria[3].
F16 (75 µM) increases state 4 oxygen consumption rate of isolated rat liver mitochondria in a dose-dependent manner, with a 3-fold increase at 75 µM, indicating an uncoupling effect[3].
F16 (20 µM) increases the metabolic thermogenic output of isolated rat liver mitochondria at 20 µM, consistent with an uncoupling effect on oxidative phosphorylation[3].
F16 causes a concentration-dependent decrease in mitochondrial membrane potential (ΔΨm) in isolated rat liver mitochondria, which is mediated by mitochondrial permeability transition (MPT)[3].
F16 (1 h) induces concentration-dependent release of cytochrome c from isolated rat liver mitochondria after 1 h of incubation at 4 °C[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:EpH4-A6 neu-overexpressing mouse mammary epithelial cells, EpH4-EV control mouse mammary epithelial cells
-
Concentration:10-15 μM; 1 μM; 100 nM
-
Incubation Time:36-40 h; (secondary screen, no time specified); (dose-response assay, no time specified)
-
Result:Selectively inhibited BrdU incorporation in EpH4-A6 cells relative to control cells at 10-15 μM.
Partially inhibited BrdU incorporation in EpH4-A6 cells at 1 μM.
Showed partial inhibition in a dose-response format at 100 nM.
-
Cell Line:neu-, v-Ha-ras-, β-catenin-, c-myc-initiated mouse tumor cell lines, human breast cancer cell lines
-
Concentration:3 μM
-
Incubation Time:3 days; 7 days
-
Result:Reduced cell number by 2-5 fold at 3 days and 10-40 fold at 7 days in neu- or v-Ha-ras-initiated mouse mammary tumor cell lines.
Reduced cell number by 2-4 fold in β-catenin-initiated mouse mammary tumor cell lines.
Showed no effect on c-myc-initiated mouse mammary tumor cell lines and v-Ha-ras-initiated mouse fibrosarcoma cell lines.
Inhibited proliferation in 8 of 10 human breast cancer cell lines, with no effect on MDA-MB-231 and MDA-MB-435.
-
Cell Line:EpH4-A6 neu-overexpressing mouse mammary epithelial cells, EpH4-EV control cells, sensitive mouse tumor cell lines, sensitive human breast cancer cell lines
-
Concentration:3 μM
-
Incubation Time:36 h (mouse cells); 3 days (human cells)
-
Result:Caused a dramatic decrease in S-phase cells and an increase in G1-phase cells in EpH4-A6 cells.
Induced similar decreases in S-phase cells in sensitive mouse tumor and human breast cancer cell lines, with most showing G1 arrest and a few showing both G1 and G2 arrest.
Caused no significant changes in EpH4-EV control cells.
-
Cell Line:EpH4-A6 neu-overexpressing mouse mammary epithelial cells, EpH4-EV control cells
-
Concentration:3 μM
-
Incubation Time:48, 60, 72 h (DNA fragmentation); 24, 48, 72 h (Annexin V/7-AAD staining); 15, 24, 48 h (cytochrome c detection)
-
Result:Induced oligonucleosomal DNA fragmentation in EpH4-A6 cells after 48, 60, and 72 h, with no fragmentation in EpH4-EV cells.
Triggered early apoptosis in a subpopulation of EpH4-A6 cells after 24 h, with increased late apoptosis or cell death at longer incubation times; no significant apoptosis in EpH4-EV cells.
Induced early cytochrome c release in EpH4-A6 cells, with loss of punctate mitochondrial staining and appearance of diffuse cytosolic staining.
-
Cell Line:EpH4-A6 neu-overexpressing mouse mammary epithelial cells, EpH4-EV control cells
-
Concentration:3 μM
-
Incubation Time:24, 48 h
-
Result:Decreased phosphotyrosine content of Neu, phosphorylated PKB, and phosphorylated MAPK in EpH4-A6 cells.
Reduced Neu and PKB protein levels in EpH4-A6 cells.
Left MAPK and β-actin levels unchanged in EpH4-A6 cells.
Caused no significant changes in EpH4-EV cells.
-
Cell Line:mouse mammary epithelial EpH4-A6 cells, Bcl-2-overexpressing EpH4-A6.C13 cells, Bcl-2-overexpressing EpH4-A6.C18 cells, mouse mammary adenocarcinoma SMF cells, Bcl-2-overexpressing SMF cells, mouse mammary tumor NF324-1C cells
-
Concentration:3 μM
-
Incubation Time:24 h, 48 h, 96 h
-
Result:Reduced EpH4-A6 cell number by 9.5-fold after 24 h and 32-fold after 96 h.
Reduced EpH4-A6.C13 cell number by 5-fold after 24 h and 20-fold after 96 h.
Reduced EpH4-A6.C18 cell number by 4.2-fold after 24 h and 19-fold after 96 h.
Reduced SMF cell number by 6.4-fold after 48 h.
Reduced Bcl-2-overexpressing SMF cell number by 3.6-fold after 48 h.
Reduced NF324-1C cell number by 2.9-fold after 48 h.
-
Cell Line:mouse mammary epithelial EpH4-A6 cells, Bcl-2-overexpressing EpH4-A6.C13 cells, Bcl-2-overexpressing EpH4-A6.C18 cells
-
Concentration:3 μM; 50 μM zVAD-fmk (Z-VAD-FMK) (HY-16658B) (co-incubated with F16); 28 mM Glucose (D-Glucose) (HY-B0389) (co-incubated with F16); 1 mM Tiron (HY-D0261) (co-incubated with F16)
-
Incubation Time:24 h, 48 h
-
Result:Induced an annexin V positive/7-AAD negative apoptotic population in EpH4-A6 cells.
Induced an annexin V negative/7-AAD positive necrotic population in Bcl-2-overexpressing EpH4-A6.C13 and EpH4-A6.C18 cells.
Caused 22% cell death in EpH4-A6 cells after 24 h, which was reduced to 11% with zVAD-fmk.
Caused 46% cell death in EpH4-A6 cells after 48 h, which was reduced to 28% with zVAD-fmk.
Caused 12% cell death in EpH4-A6.C13 cells after 24 h, which was reduced to 3% with zVAD-fmk plus glucose plus Tiron.
Caused 36% cell death in EpH4-A6.C13 cells after 48 h, which was reduced to 15% with zVAD-fmk plus glucose plus Tiron.
-
Cell Line:mouse mammary epithelial EpH4-A6 cells, Bcl-2-overexpressing EpH4-A6.C13 cells, Bcl-2-overexpressing EpH4-A6.C18 cells, mouse mammary adenocarcinoma SMF cells, Bcl-2-overexpressing SMF cells, mouse mammary tumor NF324-1C cells
-
Concentration:3 μM
-
Incubation Time:24 h
-
Result:Induced appearance of the cleaved (18 kDa) active form of caspase-3 in EpH4-A6 and SMF cells.
Showed no detectable cleaved caspase-3 in EpH4-A6.C13, EpH4-A6.C18, SMF-Bcl-2, or NF324-1C cells.
-
Cell Line:human gastric carcinoma (SGC-7901)
-
Concentration:3 µM
-
Incubation Time:24 h
-
Result:Showed strong overlap with MitoTracker® Red CM-H2XRos fluorescence, indicating selective accumulation in mitochondria.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice[1]
-
Dosage:20 mg/kg
-
Administration:i.p.
-
Result:Retarded the growth of subcutaneous tumors derived from EpH4-A6 cells.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 36098-33-6
-
性状 Solid
-
分子量 362.21
-
分子式 C16H15IN2
-
Color Yellow to orange
-
SMILES
C[N+]1=CC=C(/C=C/C2=CNC3=C2C=CC=C3)C=C1.[I-]
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶剤 & 溶解度
DMSO : ≥ 31 mg/mL (85.59 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 1 mg/mL (2.76 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (307 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Fantin VR, et al. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer cell. 2002 Jul;2(1):29-42. [Content Brief]
[2]. Fantin VR, et al. F16, a mitochondriotoxic compound, triggers apoptosis or necrosis depending on the genetic background of the target carcinoma cell. Cancer research. 2004 Jan 01;64(1):329-36. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 2.7608 mL | 13.8041 mL | 27.6083 mL | 69.0207 mL |
| DMSO | 5 mM | 0.5522 mL | 2.7608 mL | 5.5217 mL | 13.8041 mL |
| 10 mM | 0.2761 mL | 1.3804 mL | 2.7608 mL | 6.9021 mL | |
| 15 mM | 0.1841 mL | 0.9203 mL | 1.8406 mL | 4.6014 mL | |
| 20 mM | 0.1380 mL | 0.6902 mL | 1.3804 mL | 3.4510 mL | |
| 25 mM | 0.1104 mL | 0.5522 mL | 1.1043 mL | 2.7608 mL | |
| 30 mM | 0.0920 mL | 0.4601 mL | 0.9203 mL | 2.3007 mL | |
| 40 mM | 0.0690 mL | 0.3451 mL | 0.6902 mL | 1.7255 mL | |
| 50 mM | 0.0552 mL | 0.2761 mL | 0.5522 mL | 1.3804 mL | |
| 60 mM | 0.0460 mL | 0.2301 mL | 0.4601 mL | 1.1503 mL | |
| 80 mM | 0.0345 mL | 0.1726 mL | 0.3451 mL | 0.8628 mL |
F16 関連分類
HY-100395 関連分類
Powered by Bioz
- F16
- 36098-33-6
- F 16
- F-16
- Mitochondrial Metabolism
- Reactive Oxygen Species (ROS)
- Akt
- p38 MAPK
- Bcl-2 Family
- Apoptosis
- Bcl-2
- carcinoma cell mitochondria
- MAP kinase
- normal mammary epithelial cells
- human breast cancer cells
- PKB/Akt
- nude mice
- mitochondrial permeability transition pore
- Neu
- EpH4-A6 neu-overexpressing mouse mammary epithelial cells
- Inhibitor
- inhibitor
- inhibit